Results 261 to 270 of about 3,448,511 (303)
Some of the next articles are maybe not open access.
Recent Patents on Anti-Infective Drug Discovery, 2015
Pseudomonas aeruginosa is known as an opportunistic pathogen responsible for nosocomial infections. Multidrug (MDR) resistance bacteria are considered as a worldwide issue. The current research goal to investigate the antibiotic susceptibility pattern in Extended Spectrum beta-lactamase and non Extended Spectrum beta-lactamase producing P.
Akbariqomi, M. +5 more
openaire +2 more sources
Pseudomonas aeruginosa is known as an opportunistic pathogen responsible for nosocomial infections. Multidrug (MDR) resistance bacteria are considered as a worldwide issue. The current research goal to investigate the antibiotic susceptibility pattern in Extended Spectrum beta-lactamase and non Extended Spectrum beta-lactamase producing P.
Akbariqomi, M. +5 more
openaire +2 more sources
What are extended-spectrum beta-lactamases?
Journal of the American Academy of Physician Assistants, 2014The emergence and spread of extended-spectrum beta-lactamases (ESBLs) in Gram-negative bacteria pose important challenges for clinicians, as management options for these organisms are limited. The emergence of ESBL-producing Gram-negative bacteria is one of the most significant epidemiologic changes in infectious diseases during recent years.
openaire +2 more sources
Iranian Journal of Basic Medical Sciences, 2012
Objective(s) Production of extended-spectrum beta-lactamases (ESBLs) by enteric bacteria continues to be a major problem in hospitals and community. ESBLs producing bacteria cause many serious infections including urinary tract infections, peritonitis ...
Fatemeh Riyahi Zaniani +8 more
semanticscholar +1 more source
Objective(s) Production of extended-spectrum beta-lactamases (ESBLs) by enteric bacteria continues to be a major problem in hospitals and community. ESBLs producing bacteria cause many serious infections including urinary tract infections, peritonitis ...
Fatemeh Riyahi Zaniani +8 more
semanticscholar +1 more source
Extended-spectrum beta-lactamases.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007The first beta-lactamase was identified in an isolate of Escherichia coli in 1940. To date, there are >130 TEM-type and >50 sulfhydryl variable (SHV)-type beta-lactamases, mainly in E. coli, Klebsiella pneumoniae, and Proteus mirabilis but also in other members of the Enterobacteriaceae family and in some nonenteric organisms, such as Acinetobacter ...
openaire +1 more source
Extended-spectrum Beta-lactamases
Pediatric Infectious Disease Journal, 2011Allison M W, Malloy, Joseph M, Campos
openaire +2 more sources
[Appearance of extended-spectrum beta-lactamases].
Nihon rinsho. Japanese journal of clinical medicine, 1997Extended-spectrum beta-lactamases (ESBLs) are enzymes which hydrolyze broad-spectrum beta-lactam antibiotics by expanding the substrate spectra into the so-called anti-beta-lactamase beta-lactams such as oxyimino-cephalosporins, cephamycins, oxacephems, carbapenems and monobactams, conferring resistance to many kinds of beta-lactams on pathogenic ...
openaire +1 more source
Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum (beta)-lactamases.
Journal of Antimicrobial Chemotherapy, 2006N. Woodford +2 more
semanticscholar +1 more source
Extended-spectrum beta-lactamases. An overview.
Postgraduate medicine, 2009The emergence of extended-spectrum beta-lactamase (ESBL)- producing Klebsiella pneumoniae and other ESBL-producing Enterobacteriaceae is an increasing problem and presents a dilemma for clinicians. The problem is not only detection of this resistance in the microbiology laboratory, but also a therapeutic dilemma due to multiple drug resistance to ...
openaire +1 more source